# Treating Hyperexcitability in AD With Levetiracetam

> **NCT03875638** · PHASE2 · COMPLETED · sponsor: **Beth Israel Deaconess Medical Center** · enrollment: 58 (actual)

## Conditions studied

- Alzheimer Dementia
- Alzheimer Disease
- Dementia of Alzheimer Type
- Mild Cognitive Impairment

## Interventions

- **DRUG:** Levetiracetam
- **DRUG:** Placebo oral capsule

## Key facts

- **NCT ID:** NCT03875638
- **Lead sponsor:** Beth Israel Deaconess Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-22
- **Primary completion:** 2026-02-16
- **Final completion:** 2026-02-16
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2026-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03875638

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03875638, "Treating Hyperexcitability in AD With Levetiracetam". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03875638. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*